Compositions and methods for treating cancer with anti-CD38 immunotherapy
AssigneesLentigen Technology, Inc., The U.S.A., as represented by the Secretary, Department of Health and Human Services
InventorsDina Schneider, Rimas J. Orentas, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
Life of this patent
Estimating the term…
Abstract
Chimeric antigen receptors containing CD38 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
Claims13
A method of treating a hematological cancer in a human subject in need thereof, the method comprising administering to the human subject having the hematological cancer a pharmaceutical composition comprising an anti-tumor effective amount of a population of chimeric antigen receptor (CAR)-modified T cells,
- wherein the CAR-modified T cells of the population each comprise a nucleic acid sequence that encodes a CAR comprising:
- at least one extracellular antigen binding domain comprising a CD38 antigen binding domain comprising one of the amino acid sequences selected from the group consisting of the amino acid sequences of SEQ ID NO:
- 6, 8, 10, 22, and 24,at least one linker or spacer domain,at least one transmembrane domain, and at least one intracellular signaling domain,
- wherein the nucleic acid sequence comprises a promoter operably linked to the CAR encoding sequence and the CAR has an amino acid sequence selected from the group consisting of SEQ ID NO:
- 90, 92, 94, 104, and 106, and wherein the CAR-modified T cells of the population are T cells of the human subject, thereby treating the hematological cancer of the human subject.
Dependencies are inferred from the claim text.